A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2017
At a glance
- Drugs VIS 410 (Primary)
- Indications Influenza A virus infections
- Focus Adverse reactions
- Sponsors Visterra
- 13 Dec 2017 Status changed from active, no longer recruiting to completed.
- 16 Nov 2017 This trial has been completed in Latvia (End Date:2017-10-27).
- 10 Oct 2017 This trial has been completed in Bulgaria.